Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Stuttgart - Delayed Quote • EUR Ryvu Therapeutics SA (9Y4.SG) Follow Add holdings 7.66 +0.07 +(0.92%) As of 9:14:25 AM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 9Y4.SG 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 9Y4.SG View More All News Press Releases SEC Filings Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update Related Tickers BPMUF Basilea Pharmaceutica AG 47.50 0.00% AFMD Affimed N.V. 0.9700 +3.15% SGMO Sangamo Therapeutics, Inc. 0.7403 -5.93% MRNA Moderna, Inc. 27.46 +0.88%